DK1372611T3 - Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer - Google Patents

Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer

Info

Publication number
DK1372611T3
DK1372611T3 DK02732526T DK02732526T DK1372611T3 DK 1372611 T3 DK1372611 T3 DK 1372611T3 DK 02732526 T DK02732526 T DK 02732526T DK 02732526 T DK02732526 T DK 02732526T DK 1372611 T3 DK1372611 T3 DK 1372611T3
Authority
DK
Denmark
Prior art keywords
surfactant
water
soluble
staurosporin
pharmaceutical composition
Prior art date
Application number
DK02732526T
Other languages
English (en)
Inventor
Andreas Ebner
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001117049 external-priority patent/DE10117049A1/de
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1372611T3 publication Critical patent/DK1372611T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02732526T 2001-03-26 2002-03-26 Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer DK1372611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10114869 2001-03-26
DE2001117049 DE10117049A1 (de) 2001-04-05 2001-04-05 Zusammensetzung

Publications (1)

Publication Number Publication Date
DK1372611T3 true DK1372611T3 (da) 2006-09-18

Family

ID=26008913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02732526T DK1372611T3 (da) 2001-03-26 2002-03-26 Farmaceutisk sammensætning omfattende staurosporin med ringe vandoplöselighed, et overfladeaktivt stof og en vandoplöselig polymer

Country Status (15)

Country Link
US (5) US20040077232A1 (da)
EP (1) EP1372611B1 (da)
JP (1) JP4330343B2 (da)
CN (1) CN100350911C (da)
AT (1) ATE326216T1 (da)
AU (1) AU2002304784A1 (da)
BR (1) BR0208306A (da)
CA (1) CA2439097C (da)
CY (1) CY1106159T1 (da)
DE (1) DE60211494T2 (da)
DK (1) DK1372611T3 (da)
ES (1) ES2261671T3 (da)
HK (1) HK1061515A1 (da)
PT (1) PT1372611E (da)
WO (1) WO2002076432A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208245A1 (en) * 2002-03-15 2003-09-29 Kuyus, Stiftung Composition and utilization thereof for forming a protective film on nasal mucous membranes
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
PL2054040T3 (pl) * 2006-08-16 2011-09-30 Novartis Ag Sposób wytwarzania stałych dyspersji midostauryny
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
JP6003653B2 (ja) * 2011-08-17 2016-10-05 東レ株式会社 医療デバイスおよびその製造方法
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
IL280052B2 (en) * 2014-12-02 2023-09-01 Minerva Neurosciences Inc Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindolin-1-one for the treatment of schizophrenia
KR20170084736A (ko) * 2016-01-12 2017-07-21 삼성디스플레이 주식회사 표시장치
US10279048B2 (en) 2016-07-13 2019-05-07 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
US11642199B2 (en) * 2018-09-24 2023-05-09 3M Innovative Properties Company Dental appliance with cosmetic therapeutic aqueous solution
CN113797163B (zh) * 2020-06-17 2023-07-14 成都瑞沐生物医药科技有限公司 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂
WO2024131725A1 (en) * 2022-12-19 2024-06-27 Shenzhen Pharmacin Co., Ltd. Topical pharmaceutical compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3754082A (en) * 1970-06-11 1973-08-21 Richardson Merrell Inc Process and composition for botfly larvae eliminination
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
CA2291735A1 (en) * 1997-05-27 1998-12-03 Takahiro Ogawa Israpafant-containing water-base preparations
TW546151B (en) * 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression

Also Published As

Publication number Publication date
PT1372611E (pt) 2006-08-31
AU2002304784A1 (en) 2002-10-08
JP2004534739A (ja) 2004-11-18
EP1372611A2 (en) 2004-01-02
WO2002076432A2 (en) 2002-10-03
CA2439097C (en) 2010-10-12
CY1106159T1 (el) 2011-06-08
ATE326216T1 (de) 2006-06-15
DE60211494T2 (de) 2006-10-12
US20140018346A1 (en) 2014-01-16
US20080287417A1 (en) 2008-11-20
US20040077232A1 (en) 2004-04-22
DE60211494D1 (de) 2006-06-22
CN1499959A (zh) 2004-05-26
EP1372611B1 (en) 2006-05-17
US20160287707A1 (en) 2016-10-06
ES2261671T3 (es) 2006-11-16
CA2439097A1 (en) 2002-10-03
JP4330343B2 (ja) 2009-09-16
WO2002076432A3 (en) 2002-12-12
US20140303145A1 (en) 2014-10-09
CN100350911C (zh) 2007-11-28
HK1061515A1 (en) 2004-09-24
BR0208306A (pt) 2004-03-09

Similar Documents

Publication Publication Date Title
CY1106159T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει πενιχρα υδατοδιαλυτη σταυροσπορινη, επιφανειοδραστικη ουσια και υδατοδιαλυτο πολυμepες
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
ATE292453T1 (de) Antivirale arznei
DE69735002D1 (de) Osmotisches Verabreichungssystem für lösliche Dosen
WO1998040069A3 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
ATE274344T1 (de) Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium
HUP0500846A2 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
ATE541562T1 (de) Ibuprofen-suspension
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
BR0014378A (pt) Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
DE50005082D1 (de) Verfahren zu Herstellung von PULVERFÖRMIGEn SOLUBILISATIONSHILFSSTOFFEn FÜR FESTE PHARMAZEUTISCHE DARREICHUNGSFORMEN
NZ520927A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
DK1558219T3 (da) Farmaceutisk formulering af olanzapin
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
ZA200304846B (en) Use of chloroquine, hydroxychloroquine and 4 aminoquinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards HIV sensitive strains.
NO20025028L (no) 9-oksa-epotilonderivater, fremgangsmÕte for fremstilling derav samt deres anvendelse i farmasöytiske preparater
ATE340564T1 (de) Arzneimittel mit verzögerter wirkstoffabgabe